Le Lézard
Classified in: Health, Science and technology
Subjects: ASI, FDA

Samsung BioLogics Receives an additional FDA Approval for its world largest Plant's Production


- 3rd approval for Plant 2 in just 26 months since GMP ready
- CEO TH Kim "Samsung BioLogics once again demonstrated its superior quality capability with data integrity"

INCHEON, South Korea, May 24, 2018 /PRNewswire/ -- Samsung BioLogics announced today that a third monoclonal antibody Drug Substance has been licensed by the US FDA (Food and Drug Administration) for its second plant, the world's largest single plant.

With the approval, Samsung BioLogics has been approved by the FDA for the manufacture of three commercial Biologics Drug Substances at only its second plant in just 26 months since being GMP ready in 2016.

Samsung BioLogics has improved production efficiency through the installation of ten 15,000L bioreactors, a world's first, breaking industry stereotypes to install and operate only four or six bioreactors in a single bio-manufacturing plant.

Samsung BioLogics has demonstrated that both Plant 1 and Plant 2 are compliant with global GMP standards through receiving 14 global regulatory agency's approvals including FDA, EMA, and PMDA.

Although Plant 2 is 5 times larger and 10 times more complicated, Samsung BioLogics received initial manufacturing approval 6 months faster than Plant 1. This shortened time in construction and period of approval allows our clients to quickly supply their products to the market.

With its competitiveness, Samsung BioLogics has won the CMO Leadership Award presented by Life Science Leader in all six core categories for two consecutive years.

For the 2018 CMO Leadership Awards, more than 110 CMOs from around the world were evaluated on 23 performance metrics to determine winners in the six categories. Only CMO clients participate in the survey, which enhances the validity of the award.

TH Kim, CEO and President of Samsung BioLogics, said "There has been some cases recently where CMO's failure of receiving approval affects the clients' drug marketing schedule." Then he added that "Samsung BioLogics has once again demonstrated that it possesses world class Quality with Data Integrity which is critical to get global approvals. Samsung BioLogics has been striving to establish a system to completely prevent even tiny data errors that may occur during the whole production process of biopharmaceuticals from the establishment of the company and to set it up as a corporate culture.

TH Kim also said "We will continue to do our best to continuously innovate ourselves so that clients and patients can receive high quality medical products in a timely manner"

Samsung BioLogics will be attending the BIO International 2018 Conference in Boston June 4-7, 2018, as an exhibitor for the 8th year in a row to pursue additional contracts.

SOURCE Samsung Biologics


These press releases may also interest you

at 05:04
Sirnaomics Ltd. (the "Company"; together with its subsidiaries, "Sirnaomics" or the "Group"; stock code: 2257), a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics, has announced its audited...

at 04:28
GymNation, the homegrown UAE fitness brand, has today announced that due to unprecedented growth, it is reaching capacity across its 12 UAE gym locations and diversifying into a new market, brewing up a storm with the launch of its first-ever branded...

at 04:00
Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing...

at 03:30
Vicore Pharma Holding (STO:VICO)Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPFAdditional presentations include preclinical and translational data reflecting...

at 03:13
Orexo's Annual and Sustainability Report for 2023 has been published and can be downloaded at, www.orexo.com. The Swedish version of the Report is also available on the company's website in European Single Electronic Format (ESEF). A PDF version is...

at 03:05
Surge has just closed its second round of funding, raising ?7.5 million. The round was led by Eurazeo with the participation of Kima, Teampact, and MH Innov', as well as the support of historical funds Boutique Venture, HCVC, and 50 Partners Santé....



News published on and distributed by: